(VIANEWS) – Shares of BENEVOLENTAI (AEX-Index: BAI.AS) fell by a staggering 15.15% to €1.40 at 11:07 EST on Friday, after five consecutive sessions in a row of losses. AEX-Index is rising 0.29% to €774.87, after four consecutive sessions in a row of gains. This seems, up until now, a somewhat bullish trend exchanging session today.
BENEVOLENTAI’s last close was €1.65, 82.63% below its 52-week high of €9.50.
About BENEVOLENTAI
BenevolentAI S.A. operates as a clinical-stage AI-enabled drug discovery and development company. Its BenevolentAI platform powers in-house drug pipeline of drug programs. The company's therapeutic areas, include atopic dermatitis, ulcerative colitis, amyotrophic lateral sclerosis, glioblastoma multiforme, inflammatory bowel disease, antiviral, oncology, parkinson's disease, nonalcoholic steatohepatitis, fibrosis, inflammation, chronic kidney disease, and idiopathic pulmonary fibrosis. It has a collaboration with AstraZeneca to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.
Earnings Per Share
As for profitability, BENEVOLENTAI has a trailing twelve months EPS of €-1.68.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -152.53%.
More news about BENEVOLENTAI (BAI.AS).
